Sankyo prepares to renew research into type 2 diabetes drug

Sankyo is designing a new clinical trial for CS-917 for type 2 diabetes, with plans for a mid-stage study launch in the fourth quarter following discussions with the FDA. The announcement came from Sankyo's drug partner, Metabasis Therapeutics. Sankyo had halted research after seeing the level of lactic acid shoot up to dangerous levels in two patients involved in an earlier trial combining CS-917 and metformin. Researchers say that combination may be contraindicated but that a new trial could look at other combinations safely.

- read this article from the AP for more

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.